The market for Veterinary Pain Management Drugs was worth US$ 1.37 billion in 2022 and is predicted to be worth US$ 2.79 billion by 2032, growing at a 7.2% CAGR from 2022 to 2032.
| Report Attribute | Details |
|---|---|
| Veterinary Pain Management Drugs Market Value (2022) | US$ 1.37 Billion |
| Veterinary Pain Management Drugs Market Anticipated Value (2032) | US$ 2.79 Billion |
| Veterinary Pain Management Drugs Market Growth Rate (2022 to 2032) | 7.2% CAGR |
The global veterinary pain management medicines market is being pushed by factors such as the rising prevalence of painful and inflammatory disorders in animals, increased animal healthcare initiatives, and an increase in the number of companion animal owners.
During the projected period, the increasing government initiative toward animal healthcare is expected to drive the veterinary pain management pharmaceuticals market.
Changes in distribution channels are expected to stymie market expansion.
Companion animal owners typically purchase animal health items from veterinarians. Owners of companion animals have adjusted their purchasing habits, shifting their focus to internet-based retailers, retail stores, or other over-the-counter distribution channels. This change is causing companion health owners to choose human health products instead of animal health products if human health products are regarded to be less expensive alternatives.
Furthermore, consolidation of primary consumers such as veterinarians may have a negative impact on the price of companion healthcare items. Furthermore, the rising use of low-cost generic product subtitles may limit market potential. Regulators' restrictions may have a negative influence on the sales of pain relievers. Increasing costs of companion healthcare, as well as stricter laws on animal testing, may further stymie the market.
Furthermore, a lack of infrastructure may make it difficult to transfer medicines and vaccines to where they are needed due to poor transportation links, a lack of refrigeration, and a lack of laboratory networks for conducting health checks. Changes in purchasing behaviors, increased generic pharmaceuticals, low-cost human medication sublimities, and regulatory restrictions are critical variables that could severely limit market growth.
Laser Therapy is expected to grow at a healthy rate during the forecast period
Laser therapy is used to treat both chronic and acute injuries, as well as arthritis, sprains, and strains, edema caused by back disc disorders, and muscular-skeletal abnormalities. It also aids in the regeneration of nerve tissue following surgery. The most prevalent laser therapy is the therapeutic laser treatment of osteoarthritis (OA) in dogs and cats. In osteoarthritis (OA), the laser intensity should be 8-10 J/cm2. Due to the inflammation associated with the illness, laser therapy may potentially benefit tendonitis.
By adjusting the degree of emission, some laser systems can be utilized for both surgical and therapeutic reasons. Among the laser therapy brands available for veterinary pain management are B-Cure Laser, TENDLITE, Lumasoothe, iReliev, Keebomed, and MLS Laser Therapy (ASAveterinary). Product launches, collaborations, expansions, and mergers were among the techniques used by market participants.
It is a 28-watt diode-based laser with the unusual feature of mixing four separate wavelengths, which can also be regulated independently. Because of the causes, the category is predicted to increase significantly over the forecast period.
Over the forecast period, the North American region is expected to grow significantly.
The United States, as part of the North American region, is predicted to see considerable market expansion as a result of factors such as expanding pet adoption and rising per capita animal healthcare expenditure.
The increase in the number of veterinarians worldwide is expected to drive present and future market growth for veterinary pain management medications throughout the forecast period. Furthermore, highly developed, and well-established animal healthcare facilities are propelling expansion.
Veterinary pain management is a very important aspect of veterinary therapeutics. Animals suffer from pain, sometimes chronic, but however are unable to express it. Pain in animals could be associated with surgical pain, arthritis and cancer. Prevalence of chronic pain in animals is also known as “getting old” or slowing down”.
This could hamper the productivity of both farm and pet animals and their temper too. Research on reducing chronic pain in animals in ongoing leading to availability of multiple options to treat the various causes of pain in animals including pain medications, physical rehabilitation, acupuncture, laser therapy, and therapeutic massage to cite a few.
A few signs of pets in pain are reluctance to walk on slippery surfaces, frequently going up/down the stairs, selective behaviour and attempting to stand up with front legs. Others include loss of appetite, aggression, reduced activity and tail flicking.
Growing urbanization and increasing spread of isolated family units is leading to humanization of animals. Adoption of pets as companions has been increasing globally, driving the need for medicines, preventive treatments and care facilities for companion animals. Furthermore, increasing tendency to overfeed pets has been resulting in increasing obesity in pets globally.
This has been negatively impacting the health of pets, thus making them susceptible to more pain-related diseases, accelerated ageing - hence driving the demand for pain medicines.
A marked shift towards maintaining animal health and welfare has been recorded in developing countries and popularity of compounded drugs has been growing rapidly due to need for easy access to services and affordable veterinary drugs. This contributes to development of better personalized drugs which generally have higher efficacy.
Barriers include people’s lack of awareness regarding certain serious companion animal diseases as opposed to livestock diseases, which are more regularly monitored.
This phenomenon is particularly noted in many developing countries. High costs of development of new drugs, longer approval times, declining incremental innovation in veterinary therapeutics and declining R&D spend may hamper the veterinary pain management market over forecast period.
Global veterinary pain management drugs market is undergoing significant changes due to the increased priority for the pain management within veterinary fraternity.
Furthermore several companies in the market place creating awareness by means of Continuous Medical Education (CME) in veterinary pain management, this may change the market dynamics over a given period of forecast. By drug type, sub segment such as opioids and NSIDs in the global veterinary pain management drugs market are expected to grow in positive traction owing to its owing to its affordability availability and efficacy in treating the pain.
Geographically, veterinary pain management drugs market is classified into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding Japan, Japan, Middle East and Africa. North America and Europe will remain key markets for veterinary pain management drugs market due to deeper market penetration of the products and strong presence of big players in the market moreover, increasing awareness among farm owner, pet owners about the pain management in the regions.
Asia Pacific is anticipated to register positive growth owing to increased large number of animal pool and increasing trend of animal/pets adopting in the region.
Some of the players in the Global Veterinary Pain Management Drugs market are Boehringer Ingelheim, Merck & Co., Inc., Zoetis, Elanco, Bayer Pharma AG, Ceva Sante Animale and Norbrook Laboratories to name a few.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.
The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Global veterinary pain management drugs market has been segmented on the basis of drug type, route of administration, end user and region.
Based on the Drug type, the global veterinary pain management drugs market is segmented into the following:
Based on the Route of Administration, the global veterinary pain management drugs market is segmented into the following:
Based on the end user, the global veterinary pain management drugs market is segmented into the following:
The market is likely to register a CAGR of 7.2% through 2032.
The market is currently valued at US$ 1.37 Bn in 2022.
The market is likely to grow to a valuation of US$ 2.79 Bn by 2032.
North America is likely to be a leading market during the forecast period.
Explore Similar Insights
Veterinary Pain Management Drugs Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
